Why Flu Outbreaks Have Been the Worst in Nearly a Decade

The only thing worse than getting the flu is catching it after you’ve gotten a flu shot. It’s been a terrible year for outbreaks — the worst in almost a decade. Contributing to that is the high failure rate of this year’s vaccine. The current shot is just 25 percent effective against the H3N2 virus, this season’s most-often-identified strain by the Centers for Disease Control and Prevention. The experts say, with enough time and money, they can do a lot better. “There has to be a wholesale change to how we make the flu vaccine,” said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security. “We’re always setting ourselves up for vaccine mismatch and failures and the like because of the lead time in how long it takes the vaccines to be made.” Drug companies and public-health agencies are already grappling with the challenge of next year and beyond. Officials must decide several months ahead of flu season the make-up of the year’s vaccine. Flu shots are typically 40 percent to 60 percent effective in any given season, though this year fell short of that mark. The ultimate goal is a universal vaccine that would operate more like a measles inoculation than a vaccine targeted at a handful of strains of flu. The idea is to offer something closer to 90 percent protection against a disease for years — if not for life — with a single vaccine. It’s still early days. And out-maneuvering ...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized Bloomberg flu healthytime onetime Source Type: news

Related Links:

Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Publication date: Available online 9 October 2020Source: Pathology - Research and PracticeAuthor(s): Borislav A. Alexiev, Farres Obeidin, Daniel N. Johnson, Brian S. Finkelman, Rebecca Prince, Shaan N. Somani, Esther Cheng, Sandeep Samant
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Boosting the sensitivity of in vitroβ-lactam allergy diagnostic tests. Chem Commun (Camb). 2020 Oct 14;56(80):11973-11976 Authors: Peña-Mendizabal E, Morais S, Maquieira Á Abstract The synthesis of structurally new haptens and the development of suitable antigens are essential for boosting the sensitivity of drug allergy diagnostic testing. Unprecedented structural antigens for benzylpenicillin and amoxicillin are characterised and evaluated in a cohort of 70 subjects with a turnkey solution based on consumer electronics. PMID: 33033809 [PubMed - in process]
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research
[This Day] Asaba -- Delta State Government has launched the HIV Self-Testing Programme with a vow to scale up all response measures for arresting the relatively high HIV prevalence rate in the state, which places Delta as being among the highest in the country.
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Publication date: Available online 9 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce, Pilar Barranco, Javier Domínguez-Ortega, Joaquin Mullol, César Picado, Antonio Valero, Irina Bobolea, Ebymar Arismendi, Paula Ribó, Joaquín Sastre
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Emergency-use authorizations, a formerly obscure corner of regulatory law, have become a centerpiece of the government ’s response to the pandemic.
Source: NYT - Category: American Health Authors: Tags: your-feed-science Coronavirus Risks and Safety Concerns Food and Drug Administration Hahn, Stephen M (1960- ) Coronavirus (2019-nCoV) Vaccination and Immunization Clinical Trials Drugs (Pharmaceuticals) your-feed-health your-feed-healthc Source Type: news
The use of an immune-system stimulant harvested from shark liver oil in the development of some coronavirus vaccines has animal conservationists pressing for alternatives.(Image credit: Reinhard Dirscherl/ullstein bild via Getty Images)
Source: NPR Health and Science - Category: Consumer Health News Authors: Source Type: news
More News: AIDS Vaccine | Allergy | Allergy & Immunology | Centers for Disease Control and Prevention (CDC) | Cervical Cancer Vaccine | Chemistry | Cough | Epidemics | Epidemiology | Funding | Gardasil | Genetics | Genital Warts | H3N2 | HIV AIDS | Human Papillomavirus (HPV) | Infectious Diseases | Influenza | Influenza Vaccine | International Medicine & Public Health | Legislation | Measles | Measles Vaccine | Merck | Microbiology | National Institutes of Health (NIH) | Outbreaks | Pfizer | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Polio | Polio Vaccine | Respiratory Medicine | Science | Study | Vaccines | Whooping Cough | Whooping Cough (Pertussis) Vaccine